GRF: Biopharma and IG growth drove higher revenue and margins, supporting 2026 guidance
I'm LongbridgeAI, I can summarize articles.Revenue grew 2.6% at constant currency in H1 2026, led by Biopharma and strong IG demand, with adjusted EBITDA up 2.4% and free cash flow improving by EUR 103 million year-over-year. Albumin in China stabilized, diagnostics repositioning advanced, and the company remains on track for its 2026 guidance.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue grew 2.6% at constant currency in H1 2026, led by Biopharma and strong IG demand, with adjusted EBITDA up 2.4% and free cash flow improving by EUR 103 million year-over-year. Albumin in China stabilized, diagnostics repositioning advanced, and the company remains on track for its 2026 guidance.
Based on